Resize text 
Resize text 
Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium is a collaborative European project that comprises a programme to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. The European Medicines Agency (EMA) is the coordinator of PROTECT and GSK is the deputy co-ordinator of PROTECT. They manage a multi-national consortium of 29 partners including academics, regulators, SMEs and EFPIA companies.
| Latest News | |
|---|---|
| 31 August 2010 | End of Project Year 1 31 August 2010 marks the end of the first out of five project years for PROTECT. The progress report is currently under preparation, a summary of which will be made publicly available once it has been approved by the Innovative Medicines Initiative (IMI). |
| 14-15 June 2010 | IMI Stakeholder Forum The Innovative Medicines Initiative welcomed industry representatives, regulators, policy makers, scientific experts, patient representatives and science leaders at its first Stakeholder Forum in Brussels. The event featured presentations and discussions about the ongoing IMI projects, the IMI research agenda, the 3rd Call (2010) research topics and the IMI intellectual property policy. For more information Click here |
| 30 March 2010 | PROTECT has signed IMI Grant Agreement All PROTECT Consortium Partners have successfully acceded to the Grant Agreement which was signed in February between the IMI Joint Undertaking, the European Medicines Agency (PROTECT Project Coordinator) and the Danish Medicines Agency (Managing Entity of PROTECT). |